Generating Knowledge - Impacting Health
  • Home
  • About
    • Founding
    • Leadership
    • Partner Institutions
    • Research Staff
    • CAPRISA Research
      • Research Activities
    • Research Clinics
    • Policies
    • Awards
    • Financial Statements
  • Research
    • CAPRISA Studies
    • CTU Studies
    • EDCTP-funded studies
  • Scientific Publications
  • Media
    • Press Releases
    • In the Media
    • Covid-19 Weekly Updates
    • News and Events
    • Videos and Podcasts
      • Awards and Messages
      • Corporate Videos
      • Media Interviews
      • Media Podcasts
      • Presentations
      • Events
    • Brochures and Posters
    • Galleries
  • Newsletters
  • Careers
  • Fellowship Programme
  • Alumni
  • Contact

Home / News and Events / NICD unveils state-of-the art PacBio Sequel system - the first on the African continent

News and Events

NICD unveils state-of-the art PacBio Sequel system - the first on the African continent

The National Institute for Communicable Diseases (NICD) recently acquired a state-of-the art PacBio Sequel system, the first on the African Continent. The PacBio was funded through NRF grant awarded to CAPRISA Research Associate Prof Penny Moore, and Dr Arshad Ismail, head of the NICD Sequencing Core, as part of the NRF Research Infrastructure Support Programme. The PacBio Sequel System is based on Single Molecule, Real-Time (SMRT) Sequencing technology. Sequel SMRT cells contain 1 million zero-mode waveguides, and an have average read length of over 10,000 base pairs, producing 10 Gb per cell.

“Through an MRC Strategic Health Innovation Partnerships (SHIP) funded project, and working closely with Prof Carolyn Williamson’s lab at UCT, this platform will provide NICD with a powerful platform for full envelope deep sequencing in CAPRISA donors who developed broadly neutralizing antibodies, “explained Moore. “This will allow a much deeper understanding of how viral evolution shapes these antibodies.” Moore said that PacBio will also be “invaluable for understanding breakthrough infections in passive antibody trials, including the ongoing AMP trial, and the CAP256-VRC26.25 CAPRISA 012 trial which will soon begin.”

Share this article:

Back

Archives

  • Latest
  • 2018 Articles
  • 2017 Articles

Contact Us | Terms and Conditions | Privacy Policy |Legal | The CAPRISA name logo is a registered Trademark Copyright © 2022 Developed by Loud Crowd Media. All rights reserved

We use cookies to make your experience with us better. By continuing to use our website, you are agreeing to our use of cookies. To find out more see our privacy policy.

Close